S1175 Do Weight Loss Medications Reduce the Risk of Cirrhosis and HCC?

Trujillo, Silvia Blair; Kamionkowski, Sara; Walsh, Erin; Davila, Josue; Asaad, Imad

doi:10.14309/01.ajg.0000778232.15515.30

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary results from a retrospective analysis of a database containing 72 million unique patients reported that weight loss medications reduced the risk of HCC in obese populations (OR: 0.07), with orlistat and liraglutide showing statistically significant decreases (OR: 0.13, and 0.35, respectively)[ 67 ]. In addition, the meta-analysis by Ramai et al [ 68 ], which included data from major databases, indicated that bariatric surgery was associated with a reduced risk of HCC (pooled unadjusted OR: 0.40), although with high heterogeneity (I2: 79%).…”

Section: Interventions To Prevent Nafld/nash-associated Hccmentioning

confidence: 99%

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Onişor¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

Liver cancer is the sixth most commonly diagnosed cancer worldwide, with hepatocellular carcinoma (HCC) comprising most cases. Besides hepatitis B and C viral infections, heavy alcohol use, and nonalcoholic steatohepatitis (NASH)-associated advanced fibrosis/cirrhosis, several other risk factors for HCC have been identified ( i.e. old age, obesity, insulin resistance, type 2 diabetes). These might in fact partially explain the occurrence of HCC in non-cirrhotic patients without viral infection. HCC surveillance through effective screening programs is still an unmet need for many nonalcoholic fatty liver disease (NAFLD) patients, and identification of pre-cirrhotic individuals who progress to HCC represents a substantial challenge in clinical practice at the moment. Patients with NASH-cirrhosis should undergo systematic HCC surveillance, while this might be considered in patients with advanced fibrosis based on individual risk assessment. In this context, interventions that potentially prevent NAFLD/ NASH-associated HCC are needed. This paper provided an overview of evidence related to lifestyle changes ( i.e. weight loss, physical exercise, adherence to healthy dietary patterns, intake of certain dietary components, etc. ) and pharmacological interventions that might play a protective role by targeting the underlying causative factors and pathogenetic mechanisms. However, well-designed prospective studies specifically dedicated to NAFLD/NASH patients are still needed to clarify the relationship with HCC risk.

show abstract

Section: Interventions To Prevent Nafld/nash-associated Hccmentioning

confidence: 99%

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Onişor¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

S1175 Do Weight Loss Medications Reduce the Risk of Cirrhosis and HCC?

Cited by 1 publication

References 0 publications

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Contact Info

Product

Resources

About